Miranda Dollen
Biography:
Miranda Dollen has over 25 years’ experience in pharmacovigilance. She began her career at the UK regulatory agency in the pharmacovigilance business unit, before spending 7 years in the UK pharmaceutical industry. In 2004 Miranda moved to the service provider side of the business, spending 14 years at CanReg, acquired by Optum, acquired by Mapi and latterly acquired by ICON. During that time she worked with multiple organizations as a European Qualified Person for Pharmacovigilance, led the European team and spent the last 4 years of her time with ICON as Vice President, Pharmacovigilance, responsible for global pharmacovigilance activities. Since 2018 Miranda has provided independent consultancy services to the pharmaceutical industry. During her career, Miranda has worked with multiple Quality Assurance departments to develop and maintain a pharmacovigilance audit program, as well as personally conducting pharmacovigilance audits.
